Epilepsy and Autoimmunity in Pediatric Patients

Abstract

Our aim was to determine the presence and possible role of autoantibodies in epileptic patients with an undetermined etiology. Eighty epilepsy patients, who were referred to the Pediatric Neurology Department at Ankara University between November 2011 and April 2012, were enrolled in the study. Antinuclear antibodies (ANA), anticardiolipin IgG, antiphospholipid, antithyroid peroxidase, paraneoplastic, glutamic acid decarboxylase (GAD), and N-methyl-d-aspartate (NMDA) receptor antibodies were studied in our university laboratory. In addition, NMDA receptor (NMDAR), voltage-gated potassium channel (VGKC)-complex, leucine-rich, glioma inactivated 1 (LGI1) and contactin-associated protein 2 (CASPR2) antibodies were studied at the Oxford University Immunology Laboratory. The study included 35 girls (44%) and 45 boys (56%) with a mean symptom age of 8.6 ± 4.53 years. ANA was detected in 15 (18.8%), antiphospholipid Ab in 3 (3.75%), anticardiolipin Ab in 1 (1.25%), and antithyroid peroxidase in 3 (3.75%) epileptic patients. In addition, anti-GAD Ab was detected in 7 (8.75%), anti-Yo Ab in 3 (3.75%), and anti-Ma2 in 3 (3.75%) epileptic patients. Anti-VGKC was positive in 13 (16.25%) epileptic patients. We performed a pioneer study to investigate the association between autoimmunity and pediatric epilepsy and we conclude that autoimmunity should be considered in epileptic patients with an undetermined etiology.

Keywords

epilepsy - autoimmune - pediatric - onconeural antibodies - VGKC antibodies

• References

• 1 Berg AT, Berkovic SF, Brodie MJ , et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010; 51 (4) 676-685
• 2 Palace J, Lang B. Epilepsy: an autoimmune disease?. J Neurol Neurosurg Psychiatry 2000; 69 (6) 711-714
• 3 Bauer J, Bien CG. Encephalitis and epilepsy. Semin Immunopathol 2009; 31 (4) 537-544
• 4 Vincent A, Irani SR, Lang B. The growing recognition of immunotherapy-responsive seizure disorders with autoantibodies to specific neuronal proteins. Curr Opin Neurol 2010; 23 (2) 144-150
• 5 Irani SR, Bien CG, Lang B. Autoimmune epilepsies. Curr Opin Neurol 2011; 24 (2) 146-153
• 6 Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol 2008; 7 (4) 327-340
• 7 Bien CG, Urbach H, Schramm J , et al. Limbic encephalitis as a precipitating event in adult-onset temporal lobe epilepsy. Neurology 2007; 69 (12) 1236-1244
• 8 Vincent A, Buckley C, Schott JM , et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004; 127 (Pt 3) 701-712
• 9 Irani SR, Alexander S, Waters P , et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010; 133 (9) 2734-2748
• 10 Graus F, Keime-Guibert F, Reñe R , et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001; 124 (Pt 6) 1138-1148
• 11 Malter MP, Helmstaedter C, Urbach H, Vincent A, Bien CG. Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol 2010; 67 (4) 470-478
• 12 Thieben MJ, Lennon VA, Boeve BF, Aksamit AJ, Keegan M, Vernino S. Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology 2004; 62 (7) 1177-1182
• 13 Pittock SJ, Yoshikawa H, Ahlskog JE , et al. Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction. Mayo Clin Proc 2006; 81 (9) 1207-1214
• 14 Saiz A, Blanco Y, Sabater L , et al. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain 2008; 131 (Pt 10) 2553-2563
• 15 Barajas RF, Collins DE, Cha S, Geschwind MD. Adult-onset drug-refractory seizure disorder associated with anti-voltage-gated potassium-channel antibody. Epilepsia 2010; 51 (3) 473-477
• 16 Irani SR, Buckley C, Vincent A , et al. Immunotherapy-responsive seizure-like episodes with potassium channel antibodies. Neurology 2008; 71 (20) 1647-1648
• 17 Liimatainen S, Peltola M, Sabater L , et al. Clinical significance of glutamic acid decarboxylase antibodies in patients with epilepsy. Epilepsia 2010; 51 (5) 760-767
• 18 Irani SR, Michell AW, Lang B , et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 2011; 69 (5) 892-900
• 19 Verrot D, San-Marco M, Dravet C , et al. Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy. Am J Med 1997; 103 (1) 33-37
• 20 Brenner T, Sills GJ, Hart Y , et al. Prevalence of neurologic autoantibodies in cohorts of patients with new and established epilepsy. Epilepsia 2013; 54 (6) 1028-1035
• 21 Eriksson K, Peltola J, Keränen T, Haapala AM, Koivikko M. High prevalence of antiphospholipid antibodies in children with epilepsy: a controlled study of 50 cases. Epilepsy Res 2001; 46 (2) 129-137
• 22 Peltola JT, Haapala A, Isojärvi JI , et al. Antiphospholipid and antinuclear antibodies in patients with epilepsy or new-onset seizure disorders. Am J Med 2000; 109 (9) 712-717
• 23 Cimaz R, Romeo A, Scarano A , et al. Prevalence of anti-cardiolipin, anti-beta2 glycoprotein I, and anti-prothrombin antibodies in young patients with epilepsy. Epilepsia 2002; 43 (1) 52-59
• 24 McKnight K, Jiang Y, Hart Y , et al. Serum antibodies in epilepsy and seizure-associated disorders. Neurology 2005; 65 (11) 1730-1736
• 25 Bektas Ö, Yılmaz A, Kendirli T, Sıklar Z, Deda G. Hashimoto encephalopathy causing drug-resistant status epilepticus treated with plasmapheresis. Pediatr Neurol 2012; 46 (2) 132-135
• 26 Suleiman J, Brilot F, Lang B, Vincent A, Dale RC. Autoimmune epilepsy in children: case series and proposed guidelines for identification. Epilepsia 2013; 54 (6) 1036-1045
• 27 Suleiman J, Wright S, Gill D , et al. Autoantibodies to neuronal antigens in children with new-onset seizures classified according to the revised ILAE organization of seizures and epilepsies. Epilepsia 2013; 54 (12) 2091-2100
• 28 Hart IK, Waters C, Vincent A , et al. Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia. Ann Neurol 1997; 41 (2) 238-246
• 29 Irani SR, Bera K, Waters P , et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010; 133 (Pt 6) 1655-1667
• 30 Cojocaru IM, Cojocaru M. Reactions of the immune system in epilepsy. Maedica (Buchar) 2010; 5 (3) 201-206
• 31 Pardo A, González-Porque P, Gobernado JM, Jiménez-Escrig A, Lousa M. Study of antiphospholipid antibodies in patients treated with antiepileptic drugs. Neurologia 2001; 16 (1) 7-10
• 32 Inzelberg R, Korczyn AD. Lupus anticoagulant and late onset seizures. Acta Neurol Scand 1989; 79 (2) 114-118
• 33 Spreafico R, Binelli S, Bruzzone MG, Croci D, Rumi V, Angelini L. Primary antiphospholipid syndrome (PAPS) and isolated partial seizures in adolescence. A case report. Ital J Neurol Sci 1994; 15 (6) 297-301
• 34 Angelini L, Granata T, Zibordi F, Binelli S, Zorzi G, Besana C. Partial seizures associated with antiphospholipid antibodies in childhood. Neuropediatrics 1998; 29 (5) 249-253
• 35 Petty RE, Cassidy JT, Sullivan DB. Clinical correlates of antinuclear antibodies in juvenile rheumatoid arthritis. J Pediatr 1973; 83 (3) 386-389
• 36 Arroyave CM, Giambrone MJ, Rich KC, Walaszek M. The frequency of antinuclear antibody (ANA) in children by use of mouse kidney (MK) and human epithelial cells (HEp-2) as substrates. J Allergy Clin Immunol 1988; 82 (5 Pt 1) 741-744
• 37 Martini A, Lorini R, Zanaboni D, Ravelli A, Burgio RG. Frequency of autoantibodies in normal children. Am J Dis Child 1989; 143 (4) 493-496
• 38 Peschen-Rosin R, Schabet M, Dichgans J. Manifestation of Hashimoto's encephalopathy years before onset of thyroid disease. Eur Neurol 1999; 41 (2) 79-84
• 39 Manto MU, Laute MA, Aguera M, Rogemond V, Pandolfo M, Honnorat J. Effects of anti-glutamic acid decarboxylase antibodies associated with neurological diseases. Ann Neurol 2007; 61 (6) 544-551
• 40 Falip M, Carreño M, Miró J , et al. Prevalence and immunological spectrum of temporal lobe epilepsy with glutamic acid decarboxylase antibodies. Eur J Neurol 2012; 19 (6) 827-833
• 41 Gozzard P, Maddison P. Which antibody and which cancer in which paraneoplastic syndromes?. Pract Neurol 2010; 10 (5) 260-270
• 42 Petit T, Janser JC, Achour NR, Borel C, Haegele P. Paraneoplastic temporal lobe epilepsy and anti-Yo autoantibody. Ann Oncol 1997; 8 (9) 919
• 43 Paterson RW, Zandi MS, Armstrong R, Vincent A, Schott JM. Clinical relevance of positive voltage-gated potassium channel (VGKC)-complex antibodies: experience from a tertiary referral centre. J Neurol Neurosurg Psychiatry 2014; 85 (6) 625-630
• 44 Bien CG, Scheffer IE. Autoantibodies and epilepsy. Epilepsia 2011; 52 (Suppl. 03) 18-22